CardioVascular BioTherapeutics is combining its own Phase II trial data with data from another drugmaker to make its case for fast-track development of a wound-healing treatment. CVBT has licensed the data from a Merck affiliate.
The exclusive license involves clinical and scientific data, including unpublished preclinical data, regarding human fibroblast growth factor-1 for wound treatment. It also includes Phase IIa and IIb data. FGF-1 is the active pharmaceutical ingredient around which CVBT develops drug candidates for conditions characterized by inadequate blood flow to tissues or organs.
The Las Vegas biotech has added the unnamed affiliate's data to its own store of FGF-1 data gathered in the run-up to its pending Phase III trial of CVBT-141B, which targets the high-infection-risk open wounds of diabetes sufferers. Once infected, such wounds often lead to limb amputation, the company says.
The drug candidate is one of three the drugmaker is developing based on FGF-1. Among them are treatments for venous stasis ulcers, surgical wounds and burns.
- see the CVBT release